Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-986403 |
Synonyms | |
Therapy Description |
BMS-986403 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets ROR1, which potentially induce toxicity in ROR1-expressing tumor cells (NCI Drug DIctionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986403 | BMS986403|BMS 986403 | BMS-986403 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets ROR1, which potentially induce toxicity in ROR1-expressing tumor cells (NCI Drug DIctionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|